THE US Food and Drug Administration has approved the marketing of the "Dermapace System," an innovative shock-wave based device for the treatment of diabetic foot ulcers.
Dermapace uses pulses of energy, similar to sound waves, to mechanically stimulate the wound.
A study showed patients treated using the Dermapace System showed an increase in wound healing at 24 weeks, with a 44% wound closure rate - see fda.gov.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jan 18
